Patterns of aldosterone, renin level and aldosterone/renin ratio in young hypertensive patients

Sumanta Kumer Saha; Tamanna Tabassum Moni; M. Rezaul Kadir

doi:10.18203/2320-6012.ijrms20240827

Authors

Sumanta Kumer Saha Department of Medicine, Popular Medical College Hospital, Dhaka, Bangladesh
Tamanna Tabassum Moni Department of Medicine, Popular Medical College Hospital, Dhaka, Bangladesh
M. Rezaul Kadir Department of Medicine, Popular Medical College Hospital, Dhaka, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20240827

Keywords:

Aldosterone, Renin level, Aldosterone/renin ratio, Hypertension

Abstract

Background: Hypertension is a common disease that affects a vast and diverse patient group. Aldosterone, the primary human mineralocorticoid, is increasingly recognized as playing a key role in cardiovascular morbidity, and its involvement in hypertension has lately been evaluated by studies. It is estimated that it accounts for up to 13% of all hypertension patients and 20% of resistant hypertension cases. This study aimed to observe the patterns of aldosterone, renin level, and aldosterone/ renin ratio in young hypertensive patients.

Methods: This was a retrospective observational study and was conducted in the Department of Medicine Popular Medical College Hospital, Dhaka, Bangladesh during the period from June, 2023 to December, 2023. In our study, we included 124 hypertensive patients who visited the outdoor department of medicine of our hospital.

Results: In our study, we found mean age was 33.38±4.49 years. The majority (75%) of our patients were male. The mean SBP and DBP were 136.77±17.54 and 88.58±10.72 mmHg respectively. The mean aldosterone level was 148.74±125.91 pmol/L. The mean plasma renin activity and aldosterone to renin ratio were 10.03±12.04 ng/mL/hr and 22.98±28.66 respectively.

Conclusions: In our study, we aimed to determine the pattern of ARR ratio in young hypertensive patients. We found that aldosterone renin ratio (ARR) levels play a crucial role in identifying the etiological patterns of young hypertensive patients e.g. Conn's syndrome, Liddle's syndrome, etc.

Metrics

Metrics Loading ...

References

Collaborators GRF. Global, regional, and national comparative risk assessment of 79 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: A systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1659-1724.

Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23.

Conen D, Ridker PM, Buring JE, Glynn RJ. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ. 2007;335(7617):432.

Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulat. 2009;119(16):2146-52.

Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet 2014;383(9932):1899-911.

Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-5.

Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892-6.

Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism: a detectable cause of curable essential hypertension. Jama. 1965;193(3):200-6.

Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Ame Coll Cardiol. 2005;45(8):1243-8.

Connell JM, MacKenzie SM, Freel EM, Fraser R, Davies E. A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function. Endocrine Revi. 2008;29(2):133-54.

Dunn PJ, Espiner EA. Outpatient screening tests for primary aldosteronism. Austral N Zea J Medi. 1976;6(2):131-5.

Mckenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metabol. 1991;73(5):952-7.

Gordon RD. Mineralocorticoid hypertension. The Lancet. 1994;344(8917):240-3.

Lins PE, Adamson U. Plasma aldosterone-plasma renin activity ratio A simple test to identify patients with primary aldosteronism. Euro J Endocrinol. 1986;113(4):564-9.

Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metabol. 2004;89(3):1045-50.

Mulatero P, Dluhy RG, Giacchetti G, Boscaro M, Veglio F, Stewart PM. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trend Endocrinol Metabol. 2005;16(3):114-9.

Meneton P, Galan P, Bertrais S, Heudes D, Hercberg S, Menard J. High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations. J Human Hypert. 2008;22(8):550-8.

Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab. 2013;98(4):1409-16.

Grübler MR, Kienreich K, Gaksch M, Verheyen N, Fahrleitner‐Pammer A, Schmid J, et al. Aldosterone to active renin ratio is associated with nocturnal blood pressure in obese and treated hypertensive patients: the styrian hypertension study. J Clin Hypertens (Greenwich). 2014;16(4):289-94.

Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. 2008;26(7):1290-9.

Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic hypertension in Europe trial investigators. JAMA. 1999;282(6):539-46.

Mulatero P, Verhovez A, Morello F, Veglio F. Diagnosis and treatment of low-renin hypertension. Clin Endocrinol (Oxf). 2007;67(3):324-34.

Verhovez A, Mulatero P, Bertello C, Saglio E, Viola A, Tosello F, et al. Is Renin-based treatment a reasonable strategy to treat essential hypertension? High Blood Press Cardiovasc Prev. 2008;15:1-5.

Viola A, Monticone S, Burrello J, Buffolo F, Lucchiari M, Rabbia F, et al. Renin and aldosterone measurements in the management of arterial hypertension. Horm Metabol Res. 2015;47(06):418-26.

Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin II-induced target organ damage and prevention. Cardiovas Res. 2004;61(4):663-70.

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916.

Hottenga JJ, Boomsma DI, Kupper N, Posthuma D, Snieder H, Willemsen G, et al. Heritability and stability of resting blood pressure. Twin Res Hum Genet. 2005;8(5):499-508.

Levy D, DeStefano AL, Larson MG, O‘Donnell CJ, Lifton Rp, Gavras H, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotype in subjects from the Framingham heart study. Hypertension. 2000;36(4):477-83.

Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Family (parental) history and prevalence of hypertension. Results of a nationwide screening program. JAMA. 1979;241(1):43-6.

Lieb W, Pencina MJ, Wang TJ, Larson MG, Lanier KJ, Benjamin EJ, et al. Association of parental hypertension with concentration of select biomarkers in nonhypertensive offspring. Hypert. 2008;52:381-6.

Alvarez-Madrazo S, Padmanabhan S, Mayosi BM, Watkins H, Avery P, Wallace AM, et al. Familial and phenotypic associations of the aldosterone Renin ratio. J Clin Endocrinol Metab. 2009;94(11):4324-33.

Martinez-Aguayo A, Aglony M, Campino C, Garcia H, Bancalari R, Bolte L, et al. Aldosterone, plasma renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population. Hypertension. 2010;56(3):391-6.

Takimoto-Ohnishi E, Murakami K. Renin-angiotensin system research: from molecules to the whole body. J Physiol Sci. 2019;69(4):581-7.

Otto CM. Heartbeat: renin-angiotensin system blockade for prevention of cardiovascular disease. Heart. 2017;103(17):1305-7.

Nguyen G. Renin, (pro)renin and receptor: an update. Clin Sci (Lond). 2011;120(5):169-78.

Bauer JH. Age-related changes in the renin-aldosterone system: physiological effects and clinical implications. Drug Aging. 1993;3:238-45.

Wilson DM, Stevenson DK, Luetscher JA. Plasma prorenin and renin in childhood and adolescence. Ame J Dis Children. 1988;142(10):1070-2.

Fiselier T, Derkx F, Monnens L, Van Munster P, Peer P, Schalekamp M. The basal levels of active and inactive plasma renin concentration in infancy and childhood. Clin Sci (London, England: 1979). 1984;67(4):383-7.

Dillon MJ, Ryness JM. Plasma renin activity and aldosterone concentration in children. Br Med J. 1975;4(5992):316-9.

Li R, Richey PA, DiSessa TG, Alpert BS, Jones DP. Blood aldosterone-to-renin ratio, ambulatory blood pressure, and left ventricular mass in children. J Pediatr. 2009;155(2):170-5.